The DOI matches its Crossref record; 318 of the 318 references it cites were found in a registry or an index.
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
Open accessAbstract
Polymorphism in the apolipoprotein E (APOE) gene is a major genetic risk determinant of late-onset Alzheimer disease (AD), with the APOE*ε4 allele conferring an increased risk and the APOE*ε2 allele conferring a decreased risk relative to the common APOE*ε3 allele. Strong evidence from clinical and basic research suggests that a major pathway by which APOE4 increases the risk of AD is by driving earlier and more abundant amyloid pathology in the brains of APOE*ε4 carriers. The number of amyloid-β (Aβ)-dependent and Aβ-independent pathways that are known to be differentially modulated by APOE isoforms is increasing. For example, evidence is accumulating that APOE influences tau pathology, tau-mediated neurodegeneration and microglial responses to AD-related pathologies. In addition, APOE4 is either pathogenic or shows reduced efficiency in multiple brain homeostatic pathways, including lipid transport, synaptic integrity and plasticity, glucose metabolism and cerebrovascular function. Here, we review the recent progress in clinical and basic research into the role of APOE in AD pathogenesis. We also discuss how APOE can be targeted for AD therapy using a precision medicine approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“All these effects are consistent with reported roles of APOE4 in inflammation, synaptic impairment, MAPK1 signaling and downstream APP transcription, and early endosomes7,18.”
From APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE4 is associated with increased amyloid-β deposition, hyperphosphorylation and aggregation of tau, and accelerated cognitive decline4–7.”
From APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The APOE4 polymorphism alters the accessibility of the lipid-binding region, which interferes with its cholesterol and lipid transport capacity7.”
From APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE4 is the strongest genetic determinant of late-onset AD, increasing risk in a gene dose-dependent manner, whereas APOE2 confers substantial protection 1 -5 .”
From APOE2 attenuates APOE4-associated amyloid pathology and related toxicity in a mouse model of Alzheimer’s disease (2026) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“having the APOE ɛ4 coding mutation(s) increases AD risk 3–15 fold [3]”
From Association of SPI1 haplotypes with altered SPI1 gene expression and Alzheimer’s disease risk (2022) · cites this paper as [3]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These include PLCG2 P522R rare variant (rs72824905) that provides robust protection against AD (odds ratio ≈ 0.68 [1, 4], comparable to having one APOE2 allele [5]”
From PLCγ2 deficiency compromises systemic immune tolerance and erodes myelin homeostasis while enhancing oxidative metabolism in the mouse brain (2026) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE is the most important risk factor for AD and contributes significantly to the risk of developing several other neurological and nonneurological disorders (18).”
From Regulation of astrocyte lipid metabolism and ApoE secretion by the microglial oxysterol, 25-hydroxycholesterol (2023) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A single copy of the APOE-E4 allele confers a ∼ 3.7 times greater risk than the common variant, APOE-E3, whereas homozygous APOE-E4/E4 carriers have a ∼12-15 times greater risk for developing AD.”
From Regulation of astrocyte lipid metabolism and ApoE secretion by the microglial oxysterol, 25-hydroxycholesterol (2023) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE genotype is the strongest genetic risk factor for AD21, with APOE ε2 conferring protection from disease and APOE ε4 conferring higher risk, compared to the APOE ε3 allele”
From Clonal hematopoiesis is associated with protection from Alzheimer’s disease (2023) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In line with this, binding to LDLR is required by ApoE to perform its downstream effector function (50–52).”
From Secreted Apoe rewires melanoma cell state vulnerability to ferroptosis (2024) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Genome-wide association studies have consistently implicated immune-related pathways in AD susceptibility, particularly those involving microglial function [21,22].”
From Clonal Hematopoiesis of Indeterminate Potential as an Emerging Interdisciplinary Risk Factor in Alzheimer’s Disease: Current Evidence and Future Directions (2026) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“When activated, microglia, the resident immune cells of the central nervous system, play a central role in amyloid clearance, synaptic remodeling, and the regulation of inflammatory signaling within the brain [21].”
From Clonal Hematopoiesis of Indeterminate Potential as an Emerging Interdisciplinary Risk Factor in Alzheimer’s Disease: Current Evidence and Future Directions (2026) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The APOE gene is a known genetic risk factor for neurodegeneration and cardiovascular disease (CVD) [1, 2].”
From Characterization of APOE Christchurch carriers in 455,306 UK Biobank participants (2023) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“apoE4 exacerbates amyloid pathology by promoting Aβ production and aggregation, and inhibiting Aβ clearance and degradation”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Yamazaki et al 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“apoE4 aggravates the tau pathology via promoting tau phosphorylation, aggregation, propagation, and tau-mediated neurodegeneration”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Yamazaki et al 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LRP1 mediates and regulates the endocytosis of > 30 ligands, including apolipoprotein E (APOE) and amyloid-β (Aβ) [21–27]”
From LRP1 is a neuronal receptor for α-synuclein uptake and spread (2022) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Compared with APOE3, the APOE4 isoform increases AD risk and theAPOE2 isoform reduces AD risk.166”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [166]
The cited source says what the claim attributes to it.
In the citing paper
“APOE4 isoform may affects the development and progression of AD through multiple different pathways in which inflammatory regulation plays crucial role.166”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [166]
The cited source says what the claim attributes to it.
In the citing paper
“It is known that APOE is predominantly expressed in glial cells, particularly astrocytes and activated microglia, which play central roles in A β accumulation, clearance, and neuroin fl ammation 3,4 .”
From APOE2 attenuates APOE4-associated amyloid pathology and related toxicity in a mouse model of Alzheimer’s disease (2026) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Hyperphosphorylated forms of the microtubule-associated protein tau in neurons is a major hallmark of AD [2, 3].”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Multiple cohort studies have demonstrated that the APOE ε4 allele is a major genetic risk factor for AD”
From Blood PCSK9 Impacts Alzheimer's Disease Risk in an APOE Genotype‐Dependent Manner: A Prospective Cohort Study (2026) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“while the three common isoforms (APOE2, APOE3, and APOE4) influence both amyloid‐β–dependent and independent pathways implicated in AD pathogenesis [1, 2].”
From Blood PCSK9 Impacts Alzheimer's Disease Risk in an APOE Genotype‐Dependent Manner: A Prospective Cohort Study (2026) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“APOE plays a crucial role in the pathophysiology of AD, particularly in relation to Aβ and tau.43,44”
From Association of rare APOE missense variants with Alzheimer's disease in the Japanese population (2025) · cites this paper as [43]
The cited source says what the claim attributes to it.
In the citing paper
“Cerebrovascular dysfunction has been recognized as a major pathological process of AD”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Yamazaki et al 2019
The cited source says what the claim attributes to it.
In the citing paper
“with ApoE4-positive cells showing reduced function (Rawat et al., 2019; Yamazaki et al., 2019).”
From ApoE4 Impairs Neuron-Astrocyte Coupling of Fatty Acid Metabolism (2021) · cites this paper as Yamazaki et al., 2019
The cited source says what the claim attributes to it.
In the citing paper
“ApoE4 shows both loss-of-function and gain-of-toxic-function across various AD pathogenesis pathways (Yamazaki et al., 2019).”
From ApoE4 Impairs Neuron-Astrocyte Coupling of Fatty Acid Metabolism (2021) · cites this paper as Yamazaki et al., 2019
The cited source says what the claim attributes to it.
In the citing paper
“Importantly, cerebral glucose hypometabolism occurs in both the early stage of AD (Christian et al., 2020; Yamazaki et al., 2019) and epilepsy (McDonald et al., 2018; Patel, 2018).”
From APOE4 reduces hippocampal expression of phosphoglycerate kinase 1 and sodium potassium pump to enhance seizure susceptibility in mice (2026) · cites this paper as Yamazaki et al., 2019
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“We also found that LECs isolated from the meninges of 6-month-old 5xFAD mice showed significant changes in the expression of genes involved in processes such as exocytosis, phospholipase D signaling, and response to low-density lipoprotein (Extended Data Fig. 1f–k), suggesting that meningeal Aβ deposition might affect meningeal LECs early on through deleterious processes previously implicated in”
From Meningeal lymphatics affect microglia responses and anti-Aβ immunotherapy (2021) · cites this paper as [15]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“a specific ApoE4 fragment, ApoE4[Δ(166-299)], has previously been found to promote the cellular uptake of extracellular Aβ42 and resulted in increased oxidative stress [28], similar to the effect of L28P.”
From Investigation of the independent role of a rare APOE variant (L28P; APOE*4Pittsburgh) in late-onset Alzheimer disease (2023) · cites this paper as [28]
Experimental — accuracy not yet measuredIn the citing paper
“APOE is the most significant known risk factor for sporadic Alzheimer’s disease”
From APOE3 Christchurch modulates β-catenin/Wnt signaling in iPS cell-derived cerebral organoids from Alzheimer’s cases (2024) · cites this paper as Yamazaki et al., 2019
In the citing paper
“ApoE4 exhibits the strongest receptor binding and is considered a high-risk allele, while ApoE2 exhibits the weakest receptor binding and is considered protective (Yamazaki et al., 2019).”
From APOE3 Christchurch modulates β-catenin/Wnt signaling in iPS cell-derived cerebral organoids from Alzheimer’s cases (2024) · cites this paper as Yamazaki et al., 2019
In the citing paper
“APOE also affects tau pathogenesis and tau-mediated neurodegeneration [468].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [468]
In the citing paper
“In fact, 39 AD-associated genes were found within the 10th percentile of highly expressed genes in meningeal LECs, including Apoe, which is intrinsically linked to altered risk for late onset AD15,31 and was one of the few highly expressed genes found at the intersection between all three cell types (Extended Data Fig. 9o).”
From Meningeal lymphatics affect microglia responses and anti-Aβ immunotherapy (2021) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gapped BLAST and PSI-BLAST: a new generation of protein database search programs
Altschul, S. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.17.3389 · Cited by 73,302
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., et al. (2006) · Science · doi:10.1126/science.1134108 · Cited by 6,576
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium
McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C. G., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004058 · Cited by 4,476
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336
Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
Self-citation
Cited by
Sorted by citations
Items 301–400 of 1,006
The Specific Mechanism of TREM2 Regulation of Synaptic Clearance in Alzheimer’s Disease
Qin, Q., Wang, M., Yin, Y., & Tang, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.845897 · Cited by 34
Zhang, X., Chen, C., & Liu, Y. (2024) · Alzheimer's Research & Therapy · doi:10.1186/s13195-024-01430-x · Cited by 34
Kloske, C. M., Belloy, M. E., Blue, E. E., Bowman, G. R., Carrillo, M. C., Chen, X., Chiba‐Falek, O., Davis, A. A., Paolo, G. D., Garretti, F., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13877 · Cited by 33
“10,68 This dysregulated cholesterol activity is associated with reduced myelination in apoE ε 4 carriers.”
BackgroundSelf-citationShue, F., White, L. J., Hendrix, R. D., Ulrich, J. D., Henson, R. L., Knight, W., Martens, Y. A., Wang, N., Roy, B., Starling, S. C., et al. (2024) · Science Advances · doi:10.1126/sciadv.adk3674 · Cited by 33
Self-citationModeling Alzheimer’s disease using human cell derived brain organoids and 3D models
Fernandes, S., Revanna, J. S., Pratt, J. M., Hayes, N., Marchetto, M. C., & Gage, F. H. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1434945 · Cited by 33
Cacabelos, R., Martínez-Iglesias, O. A., Cacabelos, N., Carrera, I., Corzo, L., & Naidoo, V. (2024) · Life · doi:10.3390/life14121555 · Cited by 33
Alzheimer’s Disease: From Molecular Mechanisms to Promising Therapeutic Strategies
Ivanova, A. V., Kutuzova, A. D., Kuzmichev, I., & Abakumov, M. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199444 · Cited by 33
Yu, T., Tensaouti, Y., Stephanz, E. P., Chintamen, S., Rafikian, E. E., Yang, M., & Kernie, S. G. (2021) · Communications Biology · doi:10.1038/s42003-021-02841-4 · Cited by 33
Tucker, A. E., Pauneto, C. D. M. A., Barnett, A., & Coleman, L. G. (2022) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2022.886634 · Cited by 33
Dave, B. P., Shah, Y. B., Maheshwari, K. G., Mansuri, M. K. A., Prajapati, B., Postwala, H. I., & Chorawala, M. R. (2023) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-023-01408-7 · Cited by 33
Insight into the Role of Angiopoietins in Ageing-Associated Diseases
Hayashi, S.-I., Rakugi, H., & Morishita, R. (2020) · Cells · doi:10.3390/cells9122636 · Cited by 33
Maszka, P., Kwaśniak-Butowska, M., Cysewski, D., Sławek, J. W., Smolenski, R. T., & Tomczyk, M. (2023) · Metabolites · doi:10.3390/metabo13030369 · Cited by 32
Neuroinflammation and immunometabolism in neurodegenerative diseases
Lonkar, N., Latz, E., & McManus, R. M. (2025) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001356 · Cited by 32
Sugandhi, V. V., Gadhave, D. G., Ugale, A. R., Kulkarni, N. N., Nangare, S., Patil, H. P., Rath, S., Saxena, R., Lavate, A., Patel, A. T., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102775 · Cited by 32
Alzheimer’s Disease Etiology Hypotheses and Therapeutic Strategies: A Perspective
Scarano, N., Musumeci, F., Casini, B., Brullo, C., D’Ursi, P., Fossa, P., Schenone, S., & Cichero, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146980 · Cited by 32
Zhang, S., Asghar, S., Zhu, C., Ye, J., Lin, L., Liu, X., Hu, Z., Chen, Z., Shao, F., & Xiao, Y. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.05.044 · Cited by 32
Microglia and its Genetics in Alzheimer's Disease
Liang, X., Wu, H., Colt, M., Guo, X., Pluimer, B. R., Zeng, J., Dong, S., & Zhao, Z. (2021) · Current Alzheimer Research · doi:10.2174/1567205018666211105140732 · Cited by 32
Balancing cholesterol in the brain: from synthesis to disposal
Qian, L., Chai, A. B., Gelissen, I. C., & Brown, A. J. (2022) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2022.00015 · Cited by 31
Pettigrew, C. A., Nazarovs, J., Soldan, A., Singh, V., Wang, J., Hohman, T. J., Dumitrescu, L. C., Libby, J. B., Kunkle, B. W., Gross, A. L., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01206-9 · Cited by 31
Shen, R., Ardianto, C., Celia, C., Sidharta, V. M., Sasmita, P. K., Satriotomo, I., & Turana, Y. (2023) · Dementia & Neuropsychologia · doi:10.1590/1980-5764-dn-2023-0012 · Cited by 31
Madden, B. J., Singh, R. D., Haas, M., Palma, L. M. P., Sharma, A., Vargas, M. J., Gross, L., Negron, V. C., Nate, T., Charlesworth, M. C., et al. (2024) · Kidney International · doi:10.1016/j.kint.2024.02.013 · Cited by 31
Discontinued disease-modifying therapies for Alzheimer’s disease: status and future perspectives
Imbimbo, B. P., Lozupone, M., Watling, M., & Panza, F. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1795127 · Cited by 31
Nagai, N., Kawashima, H., Toda, E., Homma, K., Osada, H., Mendoza, N. A. G., Shibata, S., Uchiyama, Y., Okano, H., Tsubota, K., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-01483-2 · Cited by 32
Custodia, A., Romaus‐Sanjurjo, D., Aramburu-Núñez, M., Álvarez-Rafael, D., Vázquez‐Vázquez, L., Camino-Castiñeiras, J., Leira, Y., Peleteiro, J. M. P., Aldrey, J. M., Sobrino, T., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158082 · Cited by 31
Cui, S., Jiang, Q., & Chen, S. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101918 · Cited by 31
Liu, J., van Beusekom, H. M. M., Bu, X., Chen, G., Rosado-de-Castro, P. H., Chen, X., Chen, X., Clarkson, A. N., Farr, T. D., Fu, Y., et al. (2023) · Neuroprotection/Neuroprotection (Chichester, England. Print) · doi:10.1002/nep3.23 · Cited by 32
Nemergut, M., Marques, S. M., Uhrik, L., Vanova, T., Nezvedova, M., Gadara, D. C., Jha, D., Tulis, J., Novakova, V., Planas-Iglesias, J., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00620-9 · Cited by 30
Sian‐Hülsmann, J., & Riederer, P. F. (2024) · Journal of Neural Transmission · doi:10.1007/s00702-023-02723-5 · Cited by 30
Bio–Nano Toolbox for Precision Alzheimer's Disease Gene Therapy
Liu, Y., Xia, X., Zheng, M., & Shi, B. (2024) · Advanced Materials · doi:10.1002/adma.202314354 · Cited by 31
Zhang, Y., Cheng, Y., Tang, H., Qi, Y., Cai, X., Lu, Z., Hao, Y., Dai, A., Hou, T., Liu, H., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14173 · Cited by 30
Animal and Cellular Models of Alzheimer’s Disease: Progress, Promise, and Future Approaches
Trujillo‐Estrada, L., Sánchez‐Mejías, E., Sanchez-Varo, R. M., García‐León, J. A., Nuñez‐Diaz, C., Dávila, J. C., Vitórica, J., LaFerla, F. M., Moreno‐González, I., Gutiérrez, A., et al. (2021) · The Neuroscientist · doi:10.1177/10738584211001753 · Cited by 30
Brain energy metabolism and neurodegeneration: hints from CSF lactate levels in dementias
Bonomi, C. G., Lucia, V. D., Mascolo, A. P., Assogna, M., Motta, C., Scaricamazza, E., Sallustio, F., Mercuri, N. B., Koch, G., & Martorana, A. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.05.011 · Cited by 30
Ojo, J. O., Reed, J. M., Crynen, G. C., Vallabhaneni, P., Evans, J., Shackleton, B., Eisenbaum, M., Ringland, C., Edsell, A., MULLAN, M. J., et al. (2021) · Molecular Brain · doi:10.1186/s13041-021-00803-9 · Cited by 30
Beyond the amyloid cascade: An update of Alzheimer's disease pathophysiology
Gouilly, D., Rafiq, M., Nogueira, L., Salabert, A., Payoux, P., Péran, P., & Pariente, J. (2023) · Revue Neurologique · doi:10.1016/j.neurol.2022.12.006 · Cited by 31
Kong, Y., Huang, L., Li, W., Liu, X., Zhou, Y., Liu, C., Zhang, S., Xie, F., Zhang, Z., Jiang, D., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.609908 · Cited by 29
Self-citationWang, X., Li, H., Sheng, Y., He, B., Liu, Z., Li, W., Yu, S., Wang, J., Zhang, Y., Chen, J., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.116071 · Cited by 29
Chan, B. W. G. L., Lynch, N. B., Tran, W., Joyce, J. M., Savage, G. P., Meutermans, W. D. F., Montgomery, A. P., & Kassiou, M. (2024) · Frontiers in Chemistry · doi:10.3389/fchem.2024.1379518 · Cited by 29
Poblano, J., Castillo‐Tobías, I., Berlanga, L., Tamayo‐Ordoñez, M. C., Rodríguez‐Salazar, M. D. C., Silva‐Belmares, S. Y., Aguayo‐Morales, H., & Cobos-Puc, L. E. (2024) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.14055 · Cited by 29
Phenome-wide screening for traits causally associated with the risk of coronary artery disease
Nikpay, M., & Mohammadzadeh, S. (2020) · Journal of Human Genetics · doi:10.1038/s10038-019-0716-z · Cited by 29
Raman spectroscopy characterization of the major classes of plasma lipoproteins
Ricciardi, A., Piuri, G., Porta, M. G. D., Mazzucchelli, S., Bonizzi, A., Truffi, M., Sevieri, M., Allevi, R., Corsi, F., Cazzola, R., et al. (2020) · Vibrational Spectroscopy · doi:10.1016/j.vibspec.2020.103073 · Cited by 29
Factors Influencing Alzheimer’s Disease Risk: Whether and How They are Related to the APOE Genotype
Zhang, R., Xu, X., Yu, H., Xu, X., Wang, M., & Le, W. (2022) · Neuroscience Bulletin · doi:10.1007/s12264-021-00814-5 · Cited by 31
Chernyaeva, L., Ratti, G., Teirilä, L., Fudo, S., Rankka, U., Pelkonen, A., Korhonen, P., Leskinen, K., Keskitalo, S., Salokas, K., et al. (2023) · EMBO Reports · doi:10.15252/embr.202256467 · Cited by 29
Perez-Corredor, P., Vanderleest, T. E., Vacano, G. N., Sanchez, J. S., Villalba-Moreno, N. D., Marino, C., Krasemann, S., Mendivil-Perez, M. A., Aguillón, D., Jiménez-Del-Río, M., et al. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2024.1373568 · Cited by 28
Association of SPI1 haplotypes with altered SPI1 gene expression and Alzheimer’s disease risk
Cao, H., Initiative, A. D. N., Zhou, X., Chen, Y., Ip, F. C. F., Chen, Y., Lai, N. C. H., Lo, R. M. N., Tong, E. P. S., Mok, V. C. T., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215311 · Cited by 28
“The coding mutation APOE (cid:4) 4 is the most well-accepted AD risk genetic factor: having the APOE (cid:4) 4 coding mutation(s) increases AD risk 3–15 fold [3].”
Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer’s disease?
Vecchio, F. L., Bisceglia, P., Imbimbo, B. P., Lozupone, M., Latino, R. R., Resta, E., Leone, M., Solfrizzi, V., Greco, A., Daniele, A., et al. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221081605 · Cited by 28
Calderón‐Garcidueñas, L., Hernández-Luna, J., Aiello-Mora, M., Brito-Aguilar, R., Evelson, P., Villarreal-Ríos, R., Torres‐Jardón, R., Ayala, A., & Mukherjee, P. S. (2023) · Biomolecules · doi:10.3390/biom13060927 · Cited by 28
Mountaki, C., Dafnis, I., Panagopoulou, E. A., Vasilakopoulou, P. B., Karvelas, M., Chiou, A., Karathanos, V. Τ., & Chroni, A. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.05.022 · Cited by 28
Zhu, Y., Lin, Y., Gong, B., Zhang, Y., Su, G., & Yu, Y. (2024) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2024.116255 · Cited by 28
Liu, H., Mei, F., Ye, R., Han, X., Wang, S., Ding, Y., Zhi, Y., Pang, K., Guo, W., & Lu, B. (2024) · Cell Research · doi:10.1038/s41422-024-00957-w · Cited by 27
Apolipoprotein E-ε2 and Resistance to Atherosclerosis in Midlife: The PESA Observational Study
Toribio‐Fernández, R., Tristão‐Pereira, C., Silla-Castro, J. C., Callejas, S., Oliva, B., Fernandez‐Nueda, I., García‐Lunar, I., Pérez-Herreras, C., Ordovás, J. M., Martı́n, P., et al. (2024) · Circulation Research · doi:10.1161/circresaha.123.323921 · Cited by 27
The relationship between physical activity, apolipoprotein E ε4 carriage, and brain health
de Frutos‐Lucas, J., Cuesta, P., López‐Sanz, D., Peral‐Suárez, Á., Cuadrado‐Soto, E., Ramírez‐Toraño, F., Brown, B. M., Serrano, J. M., Laws, S. M., Rodríguez‐Rojo, I. C., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00608-3 · Cited by 27
Protein prediction for trait mapping in diverse populations
Schubert, R., Geoffroy, E., Gregga, I., Mulford, A. J., Aguet, F., Ardlie, K., Gerszten, R. E., Clish, C. B., Berg, D. V. D., Taylor, K. D., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0264341 · Cited by 28
Lozupone, M., Imbimbo, B. P., Balducci, C., Vecchio, F. L., Bisceglia, P., Latino, R. R., Leone, M. A., Dibello, V., Solfrizzi, V., Greco, A., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12728 · Cited by 28
Many or too many progesterone membrane receptors? Clinical implications
Wendler, A., & Wehling, M. (2022) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2022.10.001 · Cited by 27
Complexity of Sex Differences and Their Impact on Alzheimer’s Disease
Kadlecová, M., Freude, K., & Haukedal, H. (2023) · Biomedicines · doi:10.3390/biomedicines11051261 · Cited by 27
Boeddrich, A., Haenig, C., Neuendorf, N., Blanc, E., Ivanov, A., Kirchner, M., Schleumann, P., Bayraktaroğlu, I., Richter, M., Molenda, C., et al. (2023) · Genome Medicine · doi:10.1186/s13073-023-01206-2 · Cited by 30
Zhu, Z., Yang, Y., Xiao, Z., Zhao, Q., Wu, W., Liang, X., Luo, J., Cao, Y., Shao, M., Guo, Q., et al. (2020) · Aging Clinical and Experimental Research · doi:10.1007/s40520-020-01661-6 · Cited by 27
Physical frailty, genetic predisposition, and incident dementia: a large prospective cohort study
Gao, P., Ma, L., Wang, X.-J., Wu, B., Huang, Y., Wang, Z., Fu, Y., Ou, Y., Feng, J., Cheng, W., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02927-7 · Cited by 26
A manifesto for Alzheimer’s disease drug discovery in the era of disease-modifying therapies
Hering, H., Bussière, T., Liu, C., Glajch, K. E., Weihofen, A., Grogan, J. L., & Walsh, D. M. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00872-7 · Cited by 28
Self-citationRich, S. N., Klann, E. M., Bryant, V. E., Richards, V. L., Wijayabahu, A. T., BRYANT, K. J., Mai, V., & Cook, R. L. (2020) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2020.100168 · Cited by 27
Pyun, J., Park, Y. H., Lee, K., Kim, S., Saykin, A. J., Nho, K. T., & Initiative, A. D. N. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00259-w · Cited by 26
de Frutos‐Lucas, J., Sewell, K. R., García‐Colomo, A., Markovic, S. J., Erickson, K. I., & Brown, B. M. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01170-4 · Cited by 26
Cross interactions between Apolipoprotein E and amyloid proteins in neurodegenerative diseases
Loch, R. A., Wang, H., Perálvarez‐Marín, A., Berger, P., Nielsen, H. M., Chroni, A., & Luo, J. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.01.022 · Cited by 26
Oue, H., Yamazaki, Y., Qiao, W., Yuanxin, C., Ren, Y., Kurti, A., Shue, F., Parsons, T. M., Perkerson, R. B., Kawatani, K., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.163822 · Cited by 26
Self-citationPlant-based dietary patterns and the risk of dementia: a population-based study
de Crom, T. O. E., Steur, M., Ikram, M. K., Ikram, M. A., & Voortman, T. (2023) · Age and Ageing · doi:10.1093/ageing/afad178 · Cited by 26
Aβ oligomers peak in early stages of Alzheimer's disease preceding tau pathology
Blömeke, L., Rehn, F., Kraemer‐Schulien, V., Kutzsche, J., Pils, M., Bujnicki, T., Lewczuk, P., Kornhuber, J., Freiesleben, S. D., Schneider, L., et al. (2024) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12589 · Cited by 26
Environmental pesticide exposure and Alzheimer's disease in southern Spain: A cross-sectional study
Ruiz‐González, C., Román, P., Rueda‐Ruzafa, L., Cardona, D., Requena, M., & Alarcón, R. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.115932 · Cited by 26
Zhao, J., Ikezu, T. C., Lu, W., Macyczko, J. R., Li, Y., Lewis-Tuffin, L. J., Martens, Y. A., Ren, Y., Zhu, Y., Asmann, Y. W., et al. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03444-y · Cited by 25
Self-citationSecreted Apoe rewires melanoma cell state vulnerability to ferroptosis
More, S., Bonnereau, J., Wouters, D., Spotbeen, X., Karras, P., Rizzollo, F., Killian, T., Venken, T., Naulaerts, S., Vervoort, E., et al. (2024) · Science Advances · doi:10.1126/sciadv.adp6164 · Cited by 25
DNA Methylation Analysis of Candidate Genes Associated with Dementia in Peripheral Blood
Fransquet, P. D., Lacaze, P., Saffery, R., Phung, J., Parker, E., Shah, R. C., Murray, A., Woods, R. L., & Ryan, J. (2020) · Epigenomics · doi:10.2217/epi-2020-0236 · Cited by 25
Faraji, P., Kühn, H., & Ahmadian, S. (2024) · Journal of Molecular Neuroscience · doi:10.1007/s12031-024-02224-4 · Cited by 25
Fatima, G., Ashiquzzaman, A., Kim, S. S., Kim, Y. R., Kwon, H.-S., & Chung, E. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.106877 · Cited by 26
Gene therapy for age-related macular degeneration: a promising frontier in vision preservation
Hushmandi, K., Lam, H. Y., Wong, W., Tan, W., Daryabari, S., Reiter, R. J., Farahani, N., & Kumar, A. P. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02246-4 · Cited by 25
Pharmacological Strategies to Improve Dendritic Spines in Alzheimer’s Disease
Ettcheto, M., Busquets, O., Cano, A. C., Sánchez‐López, E., Manzine, P. R., Espinosa-Jiménez, T., Verdaguer, E., Sureda, F. X., Olloquequi, J., Castro-Torres, R. D., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-201106 · Cited by 25
APOE E2/E2 Is Associated with Slower Rate of Cognitive Decline with Age
Sweigart, B., Andersen, S. L., Gurinovich, A., Cosentino, S., Schupf, N., Perls, T. T., & Sebastiani, P. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201205 · Cited by 25
DNA methylation in genes associated with the evolution of ageing and disease: A critical review
Auley, M. T. M. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101488 · Cited by 25
Modeling the blood-brain barrier for treatment of central nervous system (CNS) diseases
Rice, O., Surian, A., & Chen, Y. (2022) · Journal of Tissue Engineering · doi:10.1177/20417314221095997 · Cited by 25
Sun, J., Qiu, J., Yang, Q., Ju, Q., Qu, R., Wang, X., Wu, L., & Xing, L. (2022) · PLoS Genetics · doi:10.1371/journal.pgen.1010392 · Cited by 25
The Genetics of Neurodevelopment in Congenital Heart Disease
Patt, E., Singhania, A., Roberts, A. E., & Morton, S. U. (2022) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2022.09.026 · Cited by 25
CRISPR-Cas9 in Alzheimer’s disease: Therapeutic trends, modalities, and challenges
Chacko, L., Chaudhary, A., Singh, B., Dewanjee, S., & Kandimalla, R. J. L. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103652 · Cited by 25
Koutsodendris, N., Blumenfeld, J. R., Agrawal, A., Traglia, M., Yip, O., Rao, A. T., Kim, M. J., Nelson, M. R., Wang, Y.-H., Grone, B. P., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113252 · Cited by 25
C/ EBPβ : A transcription factor associated with the irreversible progression of Alzheimer's disease
Yao, Q., Long, C., Yi, P., Zhang, G., Wan, W., Rao, X., Ying, J., Liang, W., & Hua, F. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14721 · Cited by 25
Axl receptor tyrosine kinase is a regulator of apolipoprotein E
Zhao, W., Fan, J., Kulic, I., Koh, C., Clark, A., Meuller, J., Engkvist, O., Barichievy, S., Raynoschek, C., Hicks, R., et al. (2020) · Molecular Brain · doi:10.1186/s13041-020-00609-1 · Cited by 25
Current peptide vaccine and immunotherapy approaches against Alzheimer’s disease
Parrocha, C. M. T., & Nowick, J. S. (2023) · Peptide Science · doi:10.1002/pep2.24289 · Cited by 24
Reduced rapid eye movement sleep in late middle-aged and older apolipoprotein E ɛ 4 allele carriers
André, C., Martineau‐Dussault, M., Baril, A., Marchi, N. A., Daneault, V., Lorrain, D., Hudon, C., Bastien, C., Petit, D., Thompson, C., et al. (2024) · SLEEP · doi:10.1093/sleep/zsae094 · Cited by 24
Zeng, X., Hou, Y., Luo, L., Ren, L., Wang, Y., Jin, X., Deng, L., Gao, Y., Zhang, D., Huang, J., et al. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.148054 · Cited by 24
Selective neuronal vulnerability in Alzheimer’s disease
Wang, Z.-T., Zhang, C. M., Wang, Y., Dong, Q., Tan, L., & Yu, J. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101114 · Cited by 24
Peleg‐Raibstein, D. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.645569 · Cited by 24
Preventing Alzheimer's disease within reach by 2025: Targeted‐risk‐AD‐prevention (TRAP) strategy
Vitali, F., Branigan, G. L., & Brinton, R. D. (2021) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12190 · Cited by 24
Veling, M. T., Nguyen, D. T., Thadani, N. N., Oster, M. E., Rollins, N. J., Brock, K. P., Bethel, N. P., Lim, S., Baker, D. A., Way, J. C., et al. (2022) · ACS Synthetic Biology · doi:10.1021/acssynbio.1c00572 · Cited by 24
Linking Diabetes to Alzheimer’s Disease: Potential Roles of Glucose Metabolism and Alpha-Glucosidase
Wee, A. S., Nhu, T. D., Khaw, K. Y., Tang, K. S., & Yeong, K. Y. (2022) · Current Neuropharmacology · doi:10.2174/1570159x21999221111102343 · Cited by 24
Waigi, E. W., Webb, R. C., Moss, M. A., Uline, M. J., McCarthy, C. G., & Wenceslau, C. F. (2023) · GeroScience · doi:10.1007/s11357-023-00748-y · Cited by 26
Evaluation of bumetanide as a potential therapeutic agent for Alzheimer’s disease
Boyarko, B., Podvin, S., Greenberg, B., Momper, J. D., Huang, Y., Gerwick, W. H., Bang, A. G., Quinti, L., Griciuc, A., Kim, D. Y., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1190402 · Cited by 24
van der Heide, F. C. T., Khawaja, A. P., Berendschot, T. T. J. M., Littlejohns, T. J., Kuźma, E., Luben, R., Patel, P. J., Foster, P. J., Bertelsen, G., von Hanno, T., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13167 · Cited by 24
Noori, M., Mahboobi, R., Nabavi-Rad, A., Jamshidizadeh, S., Fakharian, F., Yadegar, A., & Zali, M. R. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e19607 · Cited by 24
Watanabe, H., Murakami, R., Tsumagari, K., Morimoto, S., Hashimoto, T., Imaizumi, K., Sonn, I., Yamada, K., Saito, Y., Murayama, S., et al. (2023) · Stem Cell Reports · doi:10.1016/j.stemcr.2023.08.002 · Cited by 24
Hammond, T. C., Green, S. J., Jacobs, Y., Chlipala, G. E., Xing, X., Heil, S. D., Chen, A., Aware, C. B., Flemister, A., Stromberg, A. J., et al. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1227203 · Cited by 24
Ali, M. H., Alam, O., Ali, A., Ali, M. U., Parvez, S., Aldosari, E., Baboota, S., & Ali, J. (2023) · Journal of Cluster Science · doi:10.1007/s10876-023-02531-7 · Cited by 24
Chlamydia pneumoniae in Alzheimer's disease pathology
Subedi, L., Gaire, B. P., Koronyo, Y., Koronyo‐Hamaoui, M., & Crother, T. R. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1393293 · Cited by 24
Shan, X., Lu, Y., Luo, Z., Zhao, X., Mei, P., Yin, H., Guo, X., Zhou, H., Zhang, J., Huang, J., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c01206 · Cited by 23
Metadata
- Authors
- Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C.-C., & Bu, G.
- Affiliations
- Mayo Clinic in Florida (US)
- Corresponding author
- Bu, Guojun
- Venue
- Nature Reviews Neurology
- Published
- 2019-07-31
- Volume
- 15
- Issue
- 9
- Pages
- 501-518
- ISSN
- 1759-4758 (ISSN-L)
- 1759-4766
- PMC
- PMC7055192
- OpenAlex
- W2965401191
- Cited by
- 1,425
- References
- 318
- Citations by year
- 2026: 191 · 2025: 259 · 2024: 233 · 2023: 242 · 2022: 200 · 2021: 172 · 2020: 124 · 2019: 4
- FWCI
- 14.75
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Reviews Neurology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- Funders
- National Institute on Aging (RF1AG051504, R01AG027924, R37AG027924, RF1AG057181, RF1AG046205, R01AG035355)
- National Institute of Neurological Disorders and Stroke (P01NS074969)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- apolipoprotein E, APOE ε4, Alzheimer's disease, APOE polymorphism, amyloid-beta, tau pathology, neurodegeneration, microglial activation, lipid transport, synaptic plasticity, glucose metabolism, cerebrovascular function, precision medicine
- MeSH terms
- Alzheimer Disease, Apolipoproteins E, Brain, Humans, Polymorphism, Genetic, Amyloid beta-Peptides, Genetic Predisposition to Disease, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
